{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028994","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-06-17T12:05:40+00:00","discovered_at":"2026-06-17T12:10:00.326601+00:00","generated_at":"2026-06-17T12:12:35.050121+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Azitra CEO details strategic pivot to cosmetic ingredients and recombinant proteins; pauses Netherton trial","bullets":["Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.","Launches ATR-COSF, a recombinant filaggrin cosmetic ingredient; expects clinical study completion in late 2026.","In-licenses FHCC minicircle plasmids showing 100,000x improvement; targets TEV protease and T7 RNA Polymerase market (~$1B).","ATR-04 (EGFR inhibitor rash) continues enrollment with MD Anderson as new clinical site.","Pauses ATR-12 Netherton trial enrollment to redirect capital to ATR-COSF near-term milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028994","json":"https://secwatch.observer/filing/0001493152-26-028994.json","markdown":"https://secwatch.observer/filing/0001493152-26-028994.md","text":"https://secwatch.observer/filing/0001493152-26-028994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/0001493152-26-028994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:12:35.050121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}